[Form 4] Veea Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Allen Salmasi, CEO and director of Veea Inc. reported purchases tied to a public best-efforts offering. On 08/14/2025, 5,239,096 shares of common stock were acquired at $1.00 per share and 5,239,096 common warrants were issued with a $1.10 exercise price and 08/14/2030 expiration. After the transactions, Mr. Salmasi directly owned 17,388,017 shares and, indirectly through NLabs Inc., beneficial ownership increased to 21,124,580 shares. NLabs Inc., of which Mr. Salmasi is CEO and stockholder, received the shares and warrants from the offering; Mr. Salmasi disclaims beneficial ownership except to the extent of pecuniary interest. The Form 4 is signed by Allen Salmasi and NLabs Inc.'s authorized signer on 08/27/2025.

Positive

• Transparent disclosure of share and warrant issuances tied to the public offering, including prices and expiration dates
• Both direct and indirect holdings are reported with a disclaimer, clarifying ownership structure through NLabs Inc.
• Form is signed by the reporting persons, satisfying filing formalities

Negative

• No explicit description of any change in voting control or dilution impact on other shareholders
• Beneficial ownership disclaimer limits clarity about the extent of the reporting person's economic influence over the shares held by NLabs Inc.

Insights

Securities Analyst

TL;DR: CEO/director participates in public offering; significant share and warrant issuance increases reported holdings.

The filing documents an issuance and acquisition tied to a public S-1 offering where 5,239,096 common shares and matching warrants were issued at $1.00 each to NLabs Inc. and recorded by Allen Salmasi. Post-transaction direct ownership is 17.39 million shares and indirect ownership through NLabs is 21.12 million shares. The warrants carry a $1.10 exercise price and a five-year term. Disclosure includes customary disclaimer of beneficial ownership by Mr. Salmasi except for pecuniary interest. This is a standard Section 16 disclosure of financing-related securities movements rather than an open-market trade.

Corporate Governance Expert

TL;DR: Corporate officer received company securities via public offering; disclosure and disclaimers are appropriately noted.

The Form 4 clearly ties the securities to a public best-efforts offering under an S-1 registration. It identifies NLabs Inc. as the recipient of shares and warrants and discloses Mr. Salmasi's roles as CEO and director and his relationship to NLabs. The filing includes the standard disclaimer limiting claimed beneficial ownership and provides signatures dated 08/27/2025. From a governance and compliance perspective, the report meets Section 16 filing requirements by reporting both direct and indirect holdings and the nature of the indirect ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salmasi Allen

(Last) (First) (Middle)

164 EAST 83RD STREET

(Street)

NEW YORK NY 10028

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VEEA INC. [ VEEA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(2)	08/14/2025		J(1)		5,239,096	A	$1(1)	17,388,017	D
Common Stock(2)	08/14/2025		J(1)		5,239,096	A	$1(1)	21,124,580	I	Owned by NLabs, Inc.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Warrants(4)	$1.1(3)	08/14/2025		J(3)		5,239,096		08/14/2025	08/14/2030	Common Stock	5,239,096	$0.00(3)	5,239,096	D
Common Warrants(4)	$1.1(3)	08/14/2025		J(3)		5,239,096		08/14/2025	08/14/2030	Common Stock	5,239,096	$0.00(3)	5,239,096	I	Owned by NLabs, Inc.

1. Name and Address of Reporting Person^*

Salmasi Allen

(Last) (First) (Middle)

164 EAST 83RD STREET

(Street)

NEW YORK NY 10028

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

1. Name and Address of Reporting Person^*

NLabs Inc.

(Last) (First) (Middle)

164 EAST 83RD STREET

(Street)

NEW YORK NY 10028

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Shares issued in a public best-efforts offering by the Issuer on the Registration Statement (333-288878) pursuant to Form S-1, which shares were issued at a public offering price of $1.00 per share and associated common warrant, and which warrant has an exercise price of $1.10 (subject to adjustment as provided therein).

2. Consists of shares issued to NLabs Inc., a Delaware corporation, of which is Mr. Salmasi is the CEO and stockholder, pursuant to the above-mentioned offering. Mr. Salmasi disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. Warrants issued in a public best-efforts offering by the Issuer on the Registration Statement (333-288878) pursuant to Form S-1, which warrants were issued at a public offering price of $1.00 per share and associated common warrant, and which warrant has an exercise price of $1.10 (subject to adjustment as provided therein).

4. Consists of warrants issued to NLabs Inc., a Delaware corporation, of which is Mr. Salmasi is the CEO and stockholder, pursuant to the above-mentioned offering. Mr. Salmasi disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these warrants in this report shall not be deemed an admission of beneficial ownership of all of the reported warrants for purposes of Section 16 or for any other purpose.

	/s/ Allen Salmasi	08/27/2025
	NLabs Inc. By: /s/ Janice K, Smith	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Allen Salmasi report on the VEEA Form 4?

The report discloses acquisition of 5,239,096 common shares at <$1.00> and 5,239,096 warrants with a <$1.10> exercise price dated 08/14/2025.

How many Veea shares does Allen Salmasi beneficially own after the transaction?

The filing shows 17,388,017 shares directly and 21,124,580 shares beneficially when including indirect ownership through NLabs Inc.

What are the terms of the warrants issued to NLabs Inc.?

Warrants cover 5,239,096 underlying shares, have a $1.10 exercise price, and expire on 08/14/2030.

Why does Mr. Salmasi disclaim beneficial ownership of some reported securities?

The filing states Mr. Salmasi disclaims beneficial ownership of securities held by NLabs Inc., except to the extent of his pecuniary interest, clarifying indirect ownership status.

When was the Form 4 signed for these transactions?

The Form 4 is signed by Allen Salmasi and on behalf of NLabs Inc. on 08/27/2025.